Not everyone has the resources to enter Biosimilar markets
The science of #Biocon remains unseen, esp. by CSLA analysts.
A biologic compared to a generic drug.
Only ~2 companies in India (that I know of) focusing on BioBetters
Stelis and Biocon
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.